Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Hairy cell leukemia


Other Names for this Disease
  • Leukemic reticuloendotheliosis
  • HCL
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

News & Events


NCATS Co-Sponsored Conferences

  • Advancing Symptom Clusters Research on Rare Cancers, Wednesday, June 17, 2015
    Location: NIH Neuroscience Building, Bethesda, MD
    Description: <p>It is intended that the in-depth, interdisciplinary dialogue of this expert working group will formulate an emerging consensus on a working definition of symptom clusters and, specific gaps and opportunities that provide a foundation for a transformative strategic blueprint to guide future symptom cluster research in rare cancers. In addition, it is anticipated that workshop proceedings will inform a funding opportunity announcement.</p>

  • Overcoming Barriers to International Clinical Trials for Rare Cancers , Friday, December 10, 2010
    Location: Bethesda, Maryland
    Description: The goals of this conference were to introduce key institutional players to the topic of international clinical trials in rare cancers and to establish an ongoing dialogue. Participants left the meeting with a set of specific priorities that need to be enacted to promote these trials. The meeting promoted consensus on the way that resources are prioritized to address rare cancers. Participants were asked to convey the content of the meeting to their constituencies and to follow up with pilot concepts.

  • Treatment of Hairy Cell Leukemia in its Second Half-Century, Monday, April 26, 2010 - Tuesday, April 27, 2010
    Location: Wilson Hall (Building 1), 3rd floor, Bethesda, MD
    Description: Goals of this conference were to (1) disseminate current knowledge of the standard treatment of hairy cell leukemia (HCL); (2) identify the evidence (or lack thereof) on which current treatment practices are based; (3) determine needs and opportunities for clinical research to improve HCL treatment; (4) disseminate results of newer diagnostic techniques, including flow cytometry, polymerase chain reaction (PCR), and serum markers, to allow decreased reliance on bone marrow biopsy; (5) discuss recent advances in HCL biology, including the molecular characterization of HCL cells with implications for disease origination/prognosis; (6) discuss new treatments for relapse/refractory disease, including investigational agents; (7) improve patient access to treatment and clinical trials; and (8) discuss the evolving activities of the HCL Consortium, including establishing a new HCL Web site to improve access to knowledge, care givers, treatment, and clinical trials. For additional information please contact Dr. Robert Kreitman at kreitmar@mail.nih.gov

Other Names for this Disease
  • Leukemic reticuloendotheliosis
  • HCL
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.